Pharmacodynamic PAR ELISA Assay
Trevigen introduces a highly sensitive, quantitative and validated assay to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening.
Gaithersburg, MD, October 10, 2008 --(PR.com)-- Pharmacodynamic (PD) assays have recently been developed and employed early in the drug development process to assess the ability of potential drug candidates to hit their molecular target(s). These assays have the advantages of allowing molecular "proof of concept" investigations at an early stage development such as phase 0 trials. These assays also provide the opportunity to prospectively identify patients likely to respond in clinical trials.
In cancer drug development, a current molecular target of high interest is poly(ADP-ribose) polymerase-1 (PARP-1). The metabolism initiated by PARP-1 is fundamentally related to the recovery or death of cancer cells. PARP inhibitors are of particular interest in that they are very well tolerated but are selectively toxic to cancer cells deficient in homologous recombination (HR), which includes BRCA1/2 deficient breast cancer cells genetically defective in HR. Until now, the effectiveness of PARP inhibitors in cells and tissues have been difficult to assess. Trevigen solves this problem with the release of the Pharmacodynamic PAR ELISA Assay, which measures the in vivo end product of the PARP reaction called poly(ADP-ribose) or PAR. This high throughput, chemiluminescent assay kit has been validated on human peripheral blood lymphocytes and has also been shown to work with normal and tumor tissue. Using highly characterized antibodies in a sandwich ELISA format, the kit detects PAR down to 5 pg per ml. By determining PAR levels in vivo prior to and following administration of PARP inhibitors, the assay is ideal for determining the effectiveness of PARP inhibitors in many formats including in patients in clinical trials.
Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. A logical extension of the focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation. Currently, the product portfolio contains over 500 products categorized into four processes – Apoptosis, DNA Damage and Repair, Angiogenesis, and Oxidative Stress.
Related Products from Trevigen include PARP and PARG assay kits, PARP enzymes and PARP antibodies. Visit www.trevigen.com or contact them at 1-800-873-8443 or info@trevigen.com for more information.
Trevigen, Inc.
8405 Helgerman Court
Gaithersburg, MD 20877
1-800-873-8443
info@trevigen.com
www.trevigen.com
###
In cancer drug development, a current molecular target of high interest is poly(ADP-ribose) polymerase-1 (PARP-1). The metabolism initiated by PARP-1 is fundamentally related to the recovery or death of cancer cells. PARP inhibitors are of particular interest in that they are very well tolerated but are selectively toxic to cancer cells deficient in homologous recombination (HR), which includes BRCA1/2 deficient breast cancer cells genetically defective in HR. Until now, the effectiveness of PARP inhibitors in cells and tissues have been difficult to assess. Trevigen solves this problem with the release of the Pharmacodynamic PAR ELISA Assay, which measures the in vivo end product of the PARP reaction called poly(ADP-ribose) or PAR. This high throughput, chemiluminescent assay kit has been validated on human peripheral blood lymphocytes and has also been shown to work with normal and tumor tissue. Using highly characterized antibodies in a sandwich ELISA format, the kit detects PAR down to 5 pg per ml. By determining PAR levels in vivo prior to and following administration of PARP inhibitors, the assay is ideal for determining the effectiveness of PARP inhibitors in many formats including in patients in clinical trials.
Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. A logical extension of the focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation. Currently, the product portfolio contains over 500 products categorized into four processes – Apoptosis, DNA Damage and Repair, Angiogenesis, and Oxidative Stress.
Related Products from Trevigen include PARP and PARG assay kits, PARP enzymes and PARP antibodies. Visit www.trevigen.com or contact them at 1-800-873-8443 or info@trevigen.com for more information.
Trevigen, Inc.
8405 Helgerman Court
Gaithersburg, MD 20877
1-800-873-8443
info@trevigen.com
www.trevigen.com
###
Contact
Trevigen, Inc.
Shamain Dang
1-800-TREVIGEN
http://www.trevigen.com
8405 Helgerman Ct.
Gaithersburg, MD 20877
Shamain Dang
1-800-TREVIGEN
http://www.trevigen.com
8405 Helgerman Ct.
Gaithersburg, MD 20877
Contact
Categories